Biocon's partner secures insulin tenders in Malaysia
Biocon's partner Duopharma Biotech secures key insulin tenders in Malaysia. This reinforces Biocon’s footprint in diabetes care abroad. The win highlights growing international demand for its insulin products. No financials disclosed, but strategic impact is positive.
📊 STOCKS: BIOCON | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #DiabetesCare
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Next articlebajaj auto hit by ransomware attack